During the call with analysts on Thursday, Nooyi said that in drinks, the company has some "promising projects" that are going through the Food and Drug Administration review process that once marketed commercially could "potentially alter the trajectory of our cola business in a meaningful way."
But then in a filing with the Securities and Exchange Commission after the call, the company backtracked and said the innovation process was under way but that it had not yet been submitted to the FDA.
Nooyi also noted that PepsiCo continues to reduce costs in the company's American beverage business and is exploring a variety of potential structural alternatives to improve profitability and return. Early next year, it will report on the progress on those initiatives, she said. The company didn't offer any more specifics during the call with investors.
Shares of PepsiCo, based in Purchase, N.Y., added 78 cents to close at $72.28 Thursday.
For the full year, PepsiCo earned $6.18 billion, or $3.92 per share. In the previous year the company earned $6.44 billion, or $4.03 per share.
Adjusted earnings were $4.10 per share.
Annual revenue fell 2 percent to $65.49 billion from $66.5 billion.
Looking ahead, the company said it foresees 2013 earnings rising 7 percent from 2012's adjusted earnings of $4.10 per share. This implies $4.39 per share, which is what analysts had predicted for the year.
PepsiCo said that the quarterly dividend increase will begin in June.